{
  "trial_id": "NCT04384692",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health Organization classification system or diagnosis of secondary myelofibrosis (MF) as defined by the International Working Group (IWG) for Myeloproliferative Neoplasms Research and Treatment criteria",
      "label": "met"
    },
    {
      "criterion": "Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk disease by Dynamic International Prognostic Scoring System (DIPSS) or DIPSS plus",
      "label": "unknown"
    },
    {
      "criterion": "Ability to understand and the willingness to sign a written informed consent document",
      "label": "met"
    },
    {
      "criterion": "Patient must be a potential hematopoietic stem cell transplant candidate as assessed by the consenting physician",
      "label": "unknown"
    },
    {
      "criterion": "Patient must be willing to start ruxolitinib within a 6-month time period",
      "label": "met"
    },
    {
      "criterion": "Meeting criteria for part 1, as above, at time of initiation of ruxolitinib, including the ability to understand and willingness to sign a written informed consent. Patients arriving to our institution for transplant and not enrolled in part 1 may still be enrolled in part 2 if part 1 criteria are met.",
      "label": "unknown"
    },
    {
      "criterion": "Received ruxolitinib for at least 8 weeks immediately prior to conditioning and be willing to continue until 9 months post-transplant as tolerated",
      "label": "not_met"
    },
    {
      "criterion": "Performance status score: Karnofsky >= 70",
      "label": "met"
    },
    {
      "criterion": "Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr) urine creatinine clearance must be > 60 ml/min",
      "label": "unknown"
    },
    {
      "criterion": "Total serum bilirubin must be < 3 mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis",
      "label": "met"
    },
    {
      "criterion": "Transaminases must be < 3 x the upper limit of normal",
      "label": "unknown"
    },
    {
      "criterion": "Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension.",
      "label": "not_met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Contraindication to receiving ruxolitinib including: Patients who have known hypersensitivity to JAK inhibitors",
      "label": "unknown"
    },
    {
      "criterion": "Clinical or laboratory evidence of significant renal or hepatic impairment, including cirrhosis",
      "label": "not_met"
    },
    {
      "criterion": "Active uncontrolled infection",
      "label": "not_met"
    },
    {
      "criterion": "Known human immunodeficiency virus (HIV) positivity",
      "label": "unknown"
    },
    {
      "criterion": "Women who are pregnant or trying to conceive",
      "label": "met"
    },
    {
      "criterion": "History of prior allogeneic transplant",
      "label": "not_met"
    }
  ],
  "notes": "Patient is a 22yo F with systemic mastocytosis, presenting with flushing and tachycardia. She responded well to IV steroids and diphenydramine. CBC was at baseline, w/normal differential. Serum tryptase revealed a high value at 84.",
  "_meta": {
    "topic_id": "10",
    "trial_id": "NCT04384692",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}